Revolutionary Single-Dose Gene Therapy for Severe Hemophilia A Trend: A Crucial Influence on the Bleeding Disorders Treatment Market's Transformation in 2025

What industry-specific factors are fueling the growth of the bleeding disorders treatment market?
The surge in diagnosed hemophilia cases is predicted to fuel the expansion of the bleeding disorders treatment market in the future. Hemophilia is a genetically transmitted bleeding disorder characterized by improper blood clotting. Treating Hemophilia involves replacement therapy, which means replenishing the absent or insufficient blood clotting factors with human plasma concentrates or engineered clotting factors VIII or IX. For example, the World Federation of Hemophilia (WFH), a nonprofit organization based in Canada, revealed that as of 2022, 257,146 hemophilia patients had been identified globally. This includes 208,957 with Hemophilia A and 42,203 with Hemophilia B. Hence, the rising count of diagnosed hemophilia patients is a key factor propelling the bleeding disorders treatment market's growth.

Get Your Bleeding Disorders Treatment Market Report Here:
https://www.thebusinessresearchcompany.com/report/bleeding-disorders-treatment-global-market-report

What Is the projected market size and growth rate for the bleeding disorders treatment market?
The market size for treatment of bleeding disorders has experienced significant growth recently. Expect to see an increase from $16.95 billion in 2024 to $18.5 billion in 2025, indicating a compound annual growth rate (CAGR) of 9.2%. This growth during the historical period can be attributed to factors such as heightened patient awareness, improved access to healthcare, advancements in the therapies for hemophilia, and expansion of the global market.

The market for treating bleeding disorders is projected to experience significant expansion in the coming years. The market size is anticipated to reach $26.14 billion in 2029, reflecting a compound annual growth rate (CAGR) of 9.0%. Several key factors contributing to this projected growth include the growing elderly population, the rise of personalized medicine, enhanced patient advocacy and support, an increase in disposable income, and increased healthcare spending. Noteworthy trends for this period also encompass the development of individualized treatment procedures, the broadening of telehealth services, progress in clotting factor therapies, RNA-based treatments, and the accessibility of orphan drug designation.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=7843&type=smp

What new trends are reshaping the bleeding disorders treatment market and its opportunities?
In a bid to enhance the efficacy of treatment and the quality of life for patients, key companies in the bleeding disorder treatment market are honing in on the development of groundbreaking technologies such as single-dose treatment. This therapeutic strategy involves the delivery of an entire treatment in one single dose, with an aspiration to obtain sustained effects without the prerequisite for multiple dosages. For instance, in June 2023, BioMarin Pharmaceutical Inc., a firm specializing in biotechnology based in the US, unveiled BioMarin's ROCTAVIANTM (valoctocogene roxaparvovec-rvox). ROCTAVIAN is an exclusive indication for adults severely afflicted by hemophilia A (characterized as FVIII activity levels less than 1 IU/dL) who lack pre-existing antibodies to adeno-associated virus serotype 5 (AAV5), as verified by an FDA-endorsed test.

What major market segments define the scope and growth of the bleeding disorders treatment market?
The bleeding disorders treatment market covered in this report is segmented -

1) By Treatment: Desmopressin (DDAVP), Hormone Replacement Therapy, Contraceptives, Anti-Fibrinolytic or Clot-Stabilizing Drugs, Fibrin Sealants, Drugs Applied To Cuts, Pipeline Analysis
2) By Disease Type: Hemophilia A, Hemophilia B, Von Willebrand disease, Liver disease, Other Disease Types
3) By End User: Hospitals, Clinics, Specialty Clinics, Research Institutes, Other End Users

Subsegments:
1) By Desmopressin (DDAVP): Intravenous Formulations, Nasal Spray Formulations
2) By Hormone Replacement Therapy: Estrogen Therapy, Progesterone Therapy
3) By Contraceptives: Combined Oral Contraceptives, Progestin-Only Contraceptives
4) By Anti-Fibrinolytic or Clot-Stabilizing Drugs: Tranexamic Acid, Aminocaproic Acid
5) By Fibrin Sealants: Tisseel, Artiss
6) By Drugs Applied To Cuts: Antiseptics, Topical Hemostatic Agents
7) By Pipeline Analysis: Upcoming Treatments in Development, Novel Therapeutics and Technologies

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7843

Which region dominates the bleeding disorders treatment market?
North America was the largest region in the bleeding disorders treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bleeding disorders treatment market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Which key market leaders are driving the bleeding disorders treatment industry growth?
Major companies operating in the bleeding disorders treatment market include AbbVie Inc., Bayer AG, Novo Nordisk A/S, Pfizer Inc., Biogen Inc., CSL Behring Company, Grifols SA, Octapharma AG, BDI Pharma Inc., Ferring Pharmaceuticals Ltd., Xenetic Biosciences Inc., Sanofi SA, Alnylam Pharmaceuticals Inc., Novartis AG, Shire plc, Novo Nordisk, Grifols SA, F. Hoffmann-La Roche AG, Sanofi Corporation, Takeda Pharmaceutical Company Limited, Kedrion S.p.A, Biotest AG, LFB S.A, Emergent BioSolutions Inc., Bio Products Laboratory Ltd., HEMA Biologics LLC, ADMA Biologics Inc., Grifols Biologicals Inc., Octapharma Plasma Inc., Kedrion Biopharma Inc., BPL Plasma Inc., BioLife Plasma Services, CSL Plasma Ltd., Grifols Shared Services North America Inc., Octapharma USA Inc., Shire US Inc., Pfizer Canada Inc., Grifols Canada Ltd., Octapharma Canada Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=7843&type=smp

What Is Covered In The Bleeding Disorders Treatment Global Market Report?

•Market Size Forecast: Examine the bleeding disorders treatment market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the bleeding disorders treatment market for a structured understanding.
•Key Players Overview: Analyze major players in the bleeding disorders treatment market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the bleeding disorders treatment market.
•Segment Contributions: Evaluate how different segments drive overall growth in the bleeding disorders treatment market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the bleeding disorders treatment market.
•Industry Challenges: Identify potential risks and obstacles affecting the bleeding disorders treatment market.
•Competitive Landscape: Review strategic developments in the bleeding disorders treatment market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.